FBIO - コロナド・バイオサイエンシズ (Fortress Biotech Inc.) コロナド・バイオサイエンシズ

 FBIOのチャート


 FBIOの企業情報

symbol FBIO
会社名 Fortress Biotech Inc (コロナド・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 フォートレス・バイオテック(Fortress Biotech Inc.) は新規医薬品バイオテクノロジー製品を取得、開発、および商業化するバイオ医薬品会社である。特定の子会社を通じて製品を開発し、商品化する。Fortressには、免疫腫瘍学、血液学、遺伝子治療、疼痛管理、希少疾患及び皮膚科の6つの治療領域を対象とした、4つの商業ステージプログラム、25の開発ステージプログラムを含む11の事業子会社がある。Fortressは、内部開発プログラムに加えて、バイオ医薬ビジネスの専門知識と医薬品開発能力を活用し、Fortress Companiesを支援するための資金調達と管理サービスを提供する。同社の子会社には、Aevitas Therapeutics Avenue Therapeutics Caelum Biosciences Cellvation Inc. Checkpoint Therapeutics Cyprium Therapeutics Helocyte Inc. Journey Medical Corporation Mustang Bio National Holdings Corp 及び Tamid Bio Inc.を含む。   コロナド・バイオサイエンシズは、米国の生物学的薬剤メ―カ―。自己免疫疾患および癌の治療のための免疫療法と薬剤の開発に焦点を当てる。臨床開発段階の主要な製品候補は、クロ―ン病、潰瘍性大腸炎、多発性硬化症などの自己免疫疾患の治療向けCNDO-201、急性骨髄性白血病の治療向けCNDO-109。   Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest- growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high- potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital and Nationwide Children's Hospital.
本社所在地 2 Gansevoort Street 9th Floor New York NY 10014 USA
代表者氏名 Lindsay A. Rosenwald Lindsay A. Rosenwald
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 781-652-4500
設立年月日 38869
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 45人
url www.fortressbiotech.com
nasdaq_url https://www.nasdaq.com/symbol/fbio
adr_tso
EBITDA EBITDA(百万ドル) -117.12600
終値(lastsale) 1.37
時価総額(marketcap) 74449346.93
時価総額 時価総額(百万ドル) 52.44603
売上高 売上高(百万ドル) 211.46400
企業価値(EV) 企業価値(EV)(百万ドル) -0.92697
当期純利益 当期純利益(百万ドル) -37.95800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Fortress Biotech Inc revenues increased 25% to $119.3M. Net loss increased 45% to $42.6M. Revenues reflect National segment increase of 21% to $106.5M Dermatology Product segment increase of 99% to $12.2M. Higher net loss reflects Research and developement increase from $15.6M to $39.3M (expense) Total National operating expenses increase of 17% to $107.1M (expense).

 FBIOのテクニカル分析


 FBIOのニュース

   Fortress Biotech Inc. (NASDAQ:FBIO) Stock Dropped -23.60% Year-To-Date, What Analysts Expect Next?  2022/02/05 14:30:00 Marketing Sentinel
In last trading session, Fortress Biotech Inc. (NASDAQ:FBIO) saw 0.34 million shares changing hands with its beta currently measuring 2.27. Company’s recent per share price level of $1.91 trading at -$0.01 or -0.52% at ring of the bell on the day assigns it a market valuation of $192.28M. That closing price of FBIO’s stock is … Fortress Biotech Inc. (NASDAQ:FBIO) Stock Dropped -23.60% Year-To-Date, What Analysts Expect Next? Read More »
   Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21  2021/12/21 14:00:00 Intrado Digital Media
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced that Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, will ring the closing bell at the Nasdaq MarketSite in Times Square today, Tuesday, December 21, 2021 at 4:00 p.m. EST. Fortress is celebrating its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market.
   Analysts Anticipate Fortress Biotech, Inc. (NASDAQ:FBIO) Will Announce Quarterly Sales of $29.93 Million  2021/12/13 00:22:41 Dakota Financial News
Analysts predict that Fortress Biotech, Inc. (NASDAQ:FBIO) will announce $29.93 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Fortress Biotechs earnings, with the lowest sales estimate coming in at $15.15 million and the highest estimate coming in at $75.52 million. Fortress Biotech reported sales of []
   Fortress Biotech’s (FBIO) Positive Rating Reiterated at UBS Group  2021/12/10 10:14:42 Dakota Financial News
UBS Group reiterated their positive rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Tuesday, The Fly reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on FBIO. HC Wainwright reaffirmed a buy rating and set a […]
   Fortress Biotech company initiates rolling submission of CUTX-101 application for Menkes disease  2021/12/07 13:38:19 Seeking Alpha
   $29.93 Million in Sales Expected for Fortress Biotech, Inc. (NASDAQ:FBIO) This Quarter  2021/12/05 06:40:42 ETF Daily News
Brokerages predict that Fortress Biotech, Inc. (NASDAQ:FBIO) will report sales of $29.93 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Fortress Biotechs earnings. The lowest sales estimate is $15.15 million and the highest is $75.52 million. Fortress Biotech posted sales of $13.75 million in the same quarter last [] The post $29.93 Million in Sales Expected for Fortress Biotech, Inc. (NASDAQ:FBIO) This Quarter appeared first on ETF Daily News .
   Fortress Biotech Inc. (NASDAQ:FBIO) Will Likely Reach 24.00 USD!  2021/11/27 19:00:00 Stocks Register
Fortress Biotech Inc. (NASDAQ:FBIO) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.03% to the previous days close as strong demand from buyers drove the stock to $2.83. Actively observing the price movement in the last trading, the stock closed the session at $2.98, falling within a range of $2.805 Fortress Biotech Inc. (NASDAQ:FBIO) Will Likely Reach 24.00 USD! Read More »
   Prudential Financial Inc. Boosts Stock Position in Fortress Biotech, Inc. (NASDAQ:FBIO)  2021/11/26 11:10:41 Transcript Daily
Prudential Financial Inc. grew its stake in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) by 26.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 233,255 shares of the biopharmaceutical companys stock after buying an additional 48,300 shares during the period. Prudential Financial Inc.s holdings in Fortress Biotech were worth $833,000 as of its most recent []
   B. Riley Reiterates Buy Rating for Fortress Biotech (NASDAQ:FBIO)  2021/11/20 06:12:43 Transcript Daily
B. Riley reissued their buy rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Wednesday, Zacks.com reports. FBIO has been the topic of several other reports. Zacks Investment Research raised Fortress Biotech from a sell rating to a hold rating and set a $3.50 target price on the stock in a []
   Fortress Biotechs (FBIO) Buy Rating Reiterated at B. Riley  2021/11/19 13:48:49 Dakota Financial News
B. Riley reissued their buy rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Wednesday morning, Zacks.com reports. FBIO has been the subject of several other research reports. Zacks Investment Research raised shares of Fortress Biotech from a sell rating to a hold rating and set a $3.50 price target for []
   The Complete Library Of: Fortress Biotech, Inc. (NASDAQ:FBIO 5.15%), Takung Art Co., Ltd. (AMEX:TKAT 0.00%)  2021/09/30 00:05:42 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post The Complete Library Of: Fortress Biotech, Inc. (NASDAQ:FBIO 5.15%), Takung Art Co., Ltd. (AMEX:TKAT 0.00%) appeared first on Stocks Equity .
   Thinking about buying stock in Applied UV, Fortress Biotech, Geovax Labs, Amicus Therapeutics, or Lucid Group?  2021/09/29 12:30:00 PR Newswire
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, FBIO, GOVX, FOLD, and LCID. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding
   Fortress Biotech rises as AstraZenecas Alexion is set to acquire Caelum Biosciences  2021/09/29 11:37:46 Seeking Alpha
   Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech  2021/09/29 11:00:00 Intrado Digital Media
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1
   Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference  2021/09/28 12:30:00 Intrado Digital Media
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the Benzinga Healthcare Small Cap Conference, scheduled to take place from September 29-30, 2021.

 関連キーワード  (医薬品 米国株 コロナド・バイオサイエンシズ FBIO Fortress Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)